PDF herunterladen
CC BY-NC-ND 4.0 · J Lab Physicians 2021; 13(03): 238-244
DOI: 10.1055/s-0041-1730884
Original Article

Correlation of Surrogate Markers of Insulin Resistance with Fasting Insulin in Type 2 Diabetes Mellitus Patients: A Study of Malwa Population in Punjab, India

Navneet Kaur
1   Department of Biochemistry, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India
,
Gitanjali,
Ravinder Garg
2   Department of Medicine, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India
,
Chaitanya Tapasvi
3   Department of Radiodiagnosis, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India
,
Sonia Chawla
1   Department of Biochemistry, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India
,
Navdeep Kaur
1   Department of Biochemistry, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India
› Institutsangaben Funding No internal or external funding is related to this work.
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Context Insulin resistance (IR) and abnormal insulin secretion play a key role for the development of type 2 diabetes mellitus (DM).

Aims We investigated the surrogate markers of IR, i.e., Homeostasis Model Assessment (HOMA), Quantitative Insulin Sensitivity Check Index (QUICKI), McAuley, and Fasting Insulin Resistance Index (FIRI) in type 2 DM patients. Also, fasting insulin (FI) levels were estimated in type 2 diabetics. Further, the correlation of FI with other surrogate markers of IR in type 2 DM was done.

Settings and Design A hundred newly diagnosed patients with type 2 DM from Malwa population, Punjab, were considered for evaluation. Another 100 healthy individuals (age and sex-matched) were examined as controls.

Methods and Material Fasting blood glucose, FI, and lipid profile were estimated, and IR was calculated using McAuley index (McA), HOMA, QUICKI, and FIRI.

Statistical Analysis Used The statistical analysis was performed on the above-mentioned clinical interpretations. The Cohen’s kappa test was used to affirm the agreement.

Results FI levels in patients with type 2 diabetes were significantly higher (20.8 ± 9.05 µIU/L) than controls (7.93 ± 1.01 µIU/L). IR by surrogate markers was found significant in the study group. The 76% patients with type 2 diabetes ended up as resistant to insulin by FI measurement, almost equivalent to McA, 80%; HOMA, 88%; FIRI, 88%; and QUICKI, 90%. A notable correlation was highlighted between FI and McA manifesting IR (p < 0.01, r = −0.85). We calculated the statistical correlation of FI with HOMA, QUICKI, and FIRI indices (p < 0.01, r = 0.93; p < 0.01 r = −0.92; and p < 0.01, r = +0.93, respectively). The agreement visible from Cohen’s kappa test also affirms the same (k = 0.9 for McA).

Conclusion We concluded that all the surrogate markers for IR were specific when compared with FI, but in terms of sensitivity McA was found to be more sensitive as it includes markers of dyslipidemia, which is the precipitating factor of metabolic derangements so as the IR in type 2 DM.

Keywords

serum insulin - FIRI - HOMA index - insulin resistance - McAuley index - QUICKI - type 2 diabetes mellitus


Publikationsverlauf

Artikel online veröffentlicht:
06. Juli 2021

© 2021. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Rother KI. Diabetes treatment—bridging the divide. N Engl J Med 2007; 356 (15) 1499-1501
    CrossrefPubMedGoogle Scholar
  • 2 Kaiser AB, Zhang N, Van Der PluijmW. Global prevalence of type 2 diabetes over the next ten years. 2018; 67 (Suppl. 01) 1
    PubMedGoogle Scholar
  • 3 Longo DL, Fauci AS, Kasper DL. et al. Harrison’s Principles of Internal Medicine. New York: McGraw-Hill; 2022
    Google Scholar
  • 4 DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14 (03) 173-194
    CrossrefPubMedGoogle Scholar
  • 5 Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998; 16 (07) 895-906
    CrossrefPubMedGoogle Scholar
  • 6 Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985; 6 (01) 45-86
    CrossrefPubMedGoogle Scholar
  • 7 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 (07) 412-419
    CrossrefPubMedGoogle Scholar
  • 8 Katz A, Nambi SS, Mather K. et al Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85 (07) 2402-2410
    CrossrefPubMedGoogle Scholar
  • 9 McAuley KA, Williams SM, Mann JI. et al Diagnosing insulin resistance in the general population. Diabetes Care 2001; 24 (03) 460-464
    CrossrefPubMedGoogle Scholar
  • 10 Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J. A simple measure of insulin resistance. Lancet 1995; 346 (8967) 120-121
    CrossrefPubMedGoogle Scholar
  • 11 Welch S, Gebhart SS, Bergman RN, Phillips LS. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 1990; 71 (06) 1508-1518
    CrossrefPubMedGoogle Scholar
  • 12 Thomas GN, Critchley JA, Tomlinson B, Anderson PJ, Lee ZS, Chan JC. Obesity, independent of insulin resistance, is a major determinant of blood pressure in normoglycemic Hong Kong Chinese. Metabolism 2000; 49 (12) 1523-1528
    CrossrefPubMedGoogle Scholar
  • 13 American Diabetes Association. Classification and diagnosis of diabetes-2020. Diabetes Care 2020; 43 (01) 14-31
    CrossrefPubMedGoogle Scholar
  • 14 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18 (06) 499-502
    CrossrefPubMedGoogle Scholar
  • 15 Gerbitz K. Pancreatic b-cell peptides: kinetics and concentration of proinsulin, insulin and c-peptide in plasma and urine, problems with measurement methods, clinical information and literature “u overview. Clin Chem Lab Med 1980; 18: 313-326
    CrossrefGoogle Scholar
  • 16 Berry KJ, Mielke Jr PW. A generalization of Cohen’s kappa agreement measure to interval measurement and multiple raters. Educ Psychol Meas 1988; 48: 921-933
    CrossrefGoogle Scholar
  • 17 Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22 (09) 1462-1470
    CrossrefPubMedGoogle Scholar
  • 18 Bano KA, Begum M, Hussain R. Fasting blood level of insulin in non-obese and non-diabetic patients with essential hypertension. Pak J Med Res 2004; 43: 5-7
    Google Scholar
  • 19 Laakso M. How good a marker is insulin level for insulin resistance?. Am J Epidemiol 1993; 137 (09) 959-965
    CrossrefPubMedGoogle Scholar
  • 20 Mack R, Skurnick B, Sterling-Jean Y, Pedra-Nobre M, Bigg D. Fasting insulin levels as a measure of insulin resistance in American Blacks. J Med 2003; 34 (1-6) 31-38
    Google Scholar
  • 21 Simsek E, Karabay M, Aras S, Kocabay K. Investigating for insulin resistance and type 2 diabetes mellitus in obese children. Turk J Endocrinol Metab 2005; 1: 17-22
    Google Scholar
  • 22 Huguette YMC, Boris AKG, Raıssa NF, Laure NJ, Julius O. Prevalence of insulin resistance in obese Cameroonian women. J Diab Endocrinol 2010; 1: 19-26
    Google Scholar
  • 23 Rutter MK, Wilson PW, Sullivan LM, Fox CS, D’Agostino Sr RB, Meigs JB. Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease. Circulation 2008; 117 (08) 1003-1009
    CrossrefPubMedGoogle Scholar
  • 24 Conwell LS, Trost SG, Brown WJ, Batch JA. Indexes of insulin resistance and secretion in obese children and adolescents: a validation study. Diabetes Care 2004; 27 (02) 314-319
    CrossrefPubMedGoogle Scholar
  • 25 Hettihewa LM, Palangasinghe S, Jayasinghe SS, Gunasekara SW, Weerarathna TP. Comparison of insulin resistance by indirect methods-HOMA, QUICKI, and McAuley- with fasting insulin in patients with type 2 diabetes in Gale, Sri Lanka: a Pilot Study. Outline J Health Allied Sci 2006;5(1) Hettihewa LM, Palangasinghe S, Jayasinghe SS, Gunasekara SW, Weerarathna TP. Comparison of insulin resistance by indirect methods-HOMA, QUICKI, and McAuley- with fasting insulin in patients with type 2 diabetes in Gale, Sri Lanka: a Pilot Study. Outline J Health Allied Sci 2006;5(1):1–8
  • 26 Garg MK, Tandon N, Marwaha RK, Singh Y. Evaluation of surrogate markers for insulin resistance for defining metabolic syndrome in urban Indian adolescents. Indian pediatrics 2014; 51 (04) 279-284
    CrossrefPubMedGoogle Scholar
  • 27 Gates JR, Parpia B, Campbell TC, Chen J. Evaluation of the FIRI (Fasting Insulin Resistance Index) and selected plasma parameters associated with insulin resistance as predictors of cardiovascular mortality in rural Chinese women. Asia Pac J Clin Nutr 1997; 6 (03) 200-202
    PubMedGoogle Scholar
  • 28 Rudvik A, Månsson M. Evaluation of surrogate measures of insulin sensitivity—correlation with gold standard is not enough. BMC Med Res Methodol 2018; 18 (01) 64
    CrossrefPubMedGoogle Scholar
  • 29 Bonora E, Targher G, Alberiche M. et al Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23 (01) 57-63
    CrossrefPubMedGoogle Scholar
  • 30 Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. The Journal of Clinical Endocrinology& Metabolism 2004; 89 (09) 4312-4319
    CrossrefPubMedGoogle Scholar